Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open label, two-arm, Phase I-II trial, non-randomized. Arm 1: crenolanib with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin) Arm 2: crenolanib with 5-azacitidine
For each arm:
The phase I with dose-limiting toxicity (DLT) determination will use 3+3 design.
Phase II total of 52 patients (26 per arm) will be treated at established phase I dose.
Enrollment to be simultaneous to each arm.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 crenolanib besylate combination | Experimental | Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin |
|
| Arm 2 crenolanib besylate combination | Experimental | Arm 2 patients will receive crenolanib besylate and azacytidine. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Crenolanib besylate | Drug |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Response Rate of Crenolanib Besylate Combination Therapy | To determine the response rate to crenolanib. CR Complete remission (CR) response criteria include a post-baseline bone marrow (BM) biopsy or aspiration % blasts <5%, absolute neutrophil count (ANC) >1×10^9/L and platelet count >100×10^9/L. CRi response included all CR criteria met, except participant did not experience either platelet recovery or ANC recovery. Morphologic Leukemia-Free State (MLFS) response included ≤5% in % blasts in the BM aspirate or biopsy. Resistant Disease (RD) was defined as the absence of CR, CRi, CRp, PR or MLFS. Death in aplasia response include deaths occurring following chemotherapy while cytopenic with an aplastic or hypoplastic BM prior to death without evidence of persistent leukemia. | Baseline up to first documented response, persistent disease, or death (whichever occurs first), 1 year. |
Not provided
Not provided
Inclusion Criteria:
Confirmed diagnosis of refractory/relapsed AML or high-risk MDS
FLT3 mutation positive (ITD, TKD or other)
ECOG PS 0-2
Adequate liver and renal function
Negative pregnancy test
Extramedullary leukemia allowed except CNS disease
Exclusion Criteria:
Arm 1 and 2 Exclusion:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jorge Cortes, MD | M.D. Anderson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MD Anderson Cancer Center | Houston | Texas | 77030 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 1 | Patients received 60 mg TID (dose level 1) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| FG001 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 2 | Patients received 80 mg TID (dose level 2) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| FG002 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 3 | Patients received 100 mg TID (dose level 3) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| FG003 | Crenolanib With 5-azacitidine - Dose Level 1 | Patients received 60 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| FG004 | Crenolanib With 5-azacitidine - Dose Level 2 | Patients received 80 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| FG005 | Crenolanib With 5-azacitidine - Dose Level 3 | Patients received 100 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Number of participants analyzed in the arm Crenolanib With 5-azacitidine - Dose Level 3 (100mg Crenolanib) is zero as the study concluded prior to enrolling any participants on this arm.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 1 | Patients received 60 mg TID (dose level 1) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Response Rate of Crenolanib Besylate Combination Therapy | To determine the response rate to crenolanib. CR Complete remission (CR) response criteria include a post-baseline bone marrow (BM) biopsy or aspiration % blasts <5%, absolute neutrophil count (ANC) >1×10^9/L and platelet count >100×10^9/L. CRi response included all CR criteria met, except participant did not experience either platelet recovery or ANC recovery. Morphologic Leukemia-Free State (MLFS) response included ≤5% in % blasts in the BM aspirate or biopsy. Resistant Disease (RD) was defined as the absence of CR, CRi, CRp, PR or MLFS. Death in aplasia response include deaths occurring following chemotherapy while cytopenic with an aplastic or hypoplastic BM prior to death without evidence of persistent leukemia. | Number of participants analyzed in the arm Crenolanib With 5-azacitidine - Dose Level 3 (100mg Crenolanib) is zero as the study concluded prior to enrolling any participants on this arm. | Posted | Count of Participants | Participants | Baseline up to first documented response, persistent disease, or death (whichever occurs first), 1 year. |
|
From date of first dose up to 30-days after the last dose, 1 year.
The number of participants at risk for Serious Adverse Events, All-Cause Mortality and Other Adverse Events is zero in the arm Crenolanib With 5-azacitidine - Dose Level 3 (100mg TID Crenolanib) as no patients were enrolled on this arm.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 1 | Patients received 60 mg TID (dose level 1) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Febrile neutropenia | Blood and lymphatic system disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Edward McDonald | Arog Pharmaceuticals | 214-593-0500 | emcdonald@arogpharma.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | May 18, 2016 | Dec 13, 2023 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D015470 | Leukemia, Myeloid, Acute |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D015255 | Idarubicin |
| D003561 | Cytarabine |
| D001374 | Azacitidine |
| D008942 | Mitoxantrone |
| D005047 | Etoposide |
| C061400 | etoposide phosphate |
| C024352 | fludarabine |
| C042382 | fludarabine phosphate |
| D016179 | Granulocyte Colony-Stimulating Factor |
| ID | Term |
|---|---|
| D003630 | Daunorubicin |
| D018943 | Anthracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Idarubicin | Drug |
|
|
| Cytarabine | Drug |
|
|
| Azacytidine | Drug |
|
|
| Mitoxantrone | Drug |
|
|
| Etoposide | Drug |
|
|
| Fludarabine | Drug |
|
|
| G-CSF | Drug |
|
| Physician Decision |
|
| BG001 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 2 | Patients received 80 mg TID (dose level 2) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| BG002 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 3 | Patients received 100 mg TID (dose level 3) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| BG003 | Crenolanib With 5-azacitidine - Dose Level 1 | Patients received 60 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| BG004 | Crenolanib With 5-azacitidine - Dose Level 2 | Patients received 80 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| BG005 | Crenolanib With 5-azacitidine - Dose Level 3 | Patients received 100 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| BG006 | Total | Total of all reporting groups |
| years |
|
| Age, Customized | Count of Participants | Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| FLT3 Mutations | Mutations in the gene encoding the trans-membrane tyrosine kinase FLT3. The type of FLT3 mutation detected by bone marrow assessment at diagnosis was collected. Subjects had either internal tandem duplications (ITD) in the juxtamembrane domain, point mutations or deletions in the tyrosine kinase domain (TKD) or both ITD and TKD mutations together. | Count of Participants | Participants |
|
| Baseline ECOG Performance | ECOG performance status is graded by the investigator during a physical assessment. A greater ECOG grade is associated with greater impact of the disease on the ability of the subject to live. Grade 0 indicates subjects who are fully active and able to carry on all pre-disease performance. Grade 1 indicates subjects restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. Grade 2 indicates subjects who are ambulatory and capable of all selfcare but unable to carry out any work activities. | Count of Participants | Participants |
|
| Antecedent Hematological Disorder | Whether or not subjects had a prior history of antecedent hematological disease. Subjects with de novo AML do not have a history of antecedent hematological disease, while subjects with secondary AML do. | Count of Participants | Participants |
|
| Description |
|---|
| OG000 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 1 | Patients received 60 mg TID (dose level 1) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| OG001 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 2 | Patients received 80 mg TID (dose level 2) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| OG002 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 3 | Patients received 100 mg TID (dose level 3) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| OG003 | Crenolanib With 5-azacitidine - Dose Level 1 | Patients received 60 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| OG004 | Crenolanib With 5-azacitidine - Dose Level 2 | Patients received 80 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
| OG005 | Crenolanib With 5-azacitidine - Dose Level 3 | Patients received 100 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. |
|
|
| 3 |
| 3 |
| 3 |
| 3 |
| 3 |
| 3 |
| EG001 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 2 | Patients received 80 mg TID (dose level 2) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. | 5 | 5 | 5 | 5 | 5 | 5 |
| EG002 | Crenolanib With Standard Salvage Chemotherapy - Dose Level 3 | Patients received 100 mg TID (dose level 3) crenolanib combined with standard salvage chemotherapy. Salvage chemotherapy options included IA (Idarubicin (Ida) 12 mg/m2 for 3 days (d) with cytarabine (AraC) 1.5 g/m2 for 4 days (3 d if age > 60 yrs)), FLAG-Ida (Fludarabine 30 mg/m2, AraC 2g/m2 each for 5 days, and Ida 8 mg/m2 for 3 days) or MEC (Mitoxantrone 8 mg/m2, etoposide 100 mg/m2, AraC 1g/m2 all for 5 days). Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. | 8 | 12 | 12 | 12 | 12 | 12 |
| EG003 | Crenolanib With 5-azacitidine - Dose Level 1 | Patients received 60 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. | 5 | 5 | 5 | 5 | 5 | 5 |
| EG004 | Crenolanib With 5-azacitidine - Dose Level 2 | Patients received 80 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. | 3 | 3 | 3 | 3 | 3 | 3 |
| EG005 | Crenolanib With 5-azacitidine - Dose Level 3 | Patients received 100 mg TID crenolanib combined with 5-azacitidine. 5-azacitidine was given at 75 mg/m2/day for 7 days each cycle. Patients were allowed to continue receiving crenolanib for up to 365 days after the completion of cytotoxic therapy if they remained in remission. Standard rolling-6 design was implemented with dose escalation of crenolanib as follows: 60 mg TID (dose level 1), 80 mg TID (dose level 2), and 100 mg TID (dose level 3). Crenolanib was given continuously starting at the end of chemotherapy, and discontinued 3 days before the next cycle. | 0 | 0 | 0 | 0 | 0 | 0 |
| Gastrointestinal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | Systematic Assessment |
|
| Melaena | Gastrointestinal disorders | Systematic Assessment |
|
| Catheter site haemorrhage | General disorders | Systematic Assessment |
|
| Hyperbilirubinaemia | Hepatobiliary disorders | Systematic Assessment |
|
| Bacteraemia | Infections and infestations | Systematic Assessment |
|
| Cellulitis | Infections and infestations | Systematic Assessment |
|
| Diverticulitis | Infections and infestations | Systematic Assessment |
|
| Lung infection | Infections and infestations | Systematic Assessment |
|
| Pneumonia | Infections and infestations | Systematic Assessment |
|
| Pneumonia fungal | Infections and infestations | Systematic Assessment |
|
| Pseudomonas infection | Infections and infestations | Systematic Assessment |
|
| Sepsis | Infections and infestations | Systematic Assessment |
|
| Septic arthritis staphylococcal | Infections and infestations | Systematic Assessment |
|
| Sinusitis | Infections and infestations | Systematic Assessment |
|
| Subdural haemorrhage | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Joint swelling | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Mental status changes | Psychiatric disorders | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Dermatitis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Hypotension | Vascular disorders | Systematic Assessment |
|
| Febrile neutropenia | Blood and lymphatic system disorders | Systematic Assessment |
|
| Leukocytosis | Blood and lymphatic system disorders | Systematic Assessment |
|
| Splenomegaly | Blood and lymphatic system disorders | Systematic Assessment |
|
| Thrombocytopenia | Blood and lymphatic system disorders | Systematic Assessment |
|
| Atrial fibrillation | Cardiac disorders | Systematic Assessment |
|
| Palpitations | Cardiac disorders | Systematic Assessment |
|
| Pericardial effusion | Cardiac disorders | Systematic Assessment |
|
| Sinus bradycardia | Cardiac disorders | Systematic Assessment |
|
| Sinus tachycardia | Cardiac disorders | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | Systematic Assessment |
|
| Arnold-Chiari malformation | Congenital, familial and genetic disorders | Systematic Assessment |
|
| Ear discomfort | Ear and labyrinth disorders | Systematic Assessment |
|
| Ear pain | Ear and labyrinth disorders | Systematic Assessment |
|
| Otorrhoea | Ear and labyrinth disorders | Systematic Assessment |
|
| Conjunctival haemorrhage | Eye disorders | Systematic Assessment |
|
| Conjunctival oedema | Eye disorders | Systematic Assessment |
|
| Dry eye | Eye disorders | Systematic Assessment |
|
| Erythema of eyelid | Eye disorders | Systematic Assessment |
|
| Eye pain | Eye disorders | Systematic Assessment |
|
| Eye pruritus | Eye disorders | Systematic Assessment |
|
| Lacrimation increased | Eye disorders | Systematic Assessment |
|
| Ocular hyperaemia | Eye disorders | Systematic Assessment |
|
| Periorbital oedema | Eye disorders | Systematic Assessment |
|
| Photophobia | Eye disorders | Systematic Assessment |
|
| Vision blurred | Eye disorders | Systematic Assessment |
|
| Vision impaired | Eye disorders | Systematic Assessment |
|
| Abdominal distension | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | Systematic Assessment |
|
| Anal fissure | Gastrointestinal disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | Systematic Assessment |
|
| Dry mouth | Gastrointestinal disorders | Systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | Systematic Assessment |
|
| Dysphagia | Gastrointestinal disorders | Systematic Assessment |
|
| Gastrointestinal hemorrhage | Gastrointestinal disorders | Systematic Assessment |
|
| Gastrooesophageal reflux disease | Gastrointestinal disorders | Systematic Assessment |
|
| Gingival bleeding | Gastrointestinal disorders | Systematic Assessment |
|
| Gingival recession | Gastrointestinal disorders | Systematic Assessment |
|
| Gingival swelling | Gastrointestinal disorders | Systematic Assessment |
|
| Haemorrhoids | Gastrointestinal disorders | Systematic Assessment |
|
| Haematochezia | Gastrointestinal disorders | Systematic Assessment |
|
| Lip pain | Gastrointestinal disorders | Systematic Assessment |
|
| Melaena | Gastrointestinal disorders | Systematic Assessment |
|
| Mouth haemorrhage | Gastrointestinal disorders | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
|
| Odonophagia | Gastrointestinal disorders | Systematic Assessment |
|
| Oral mucosal blistering | Gastrointestinal disorders | Systematic Assessment |
|
| Rectal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
|
| Stomatitis | Gastrointestinal disorders | Systematic Assessment |
|
| Upper gastrointestinal haemorrhage | Gastrointestinal disorders | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Asthenia | General disorders | Systematic Assessment |
|
| Catheter site erythema | General disorders | Systematic Assessment |
|
| Catheter site pain | General disorders | Systematic Assessment |
|
| Catheter site haemorrhage | General disorders | Systematic Assessment |
|
| Chest discomfort | General disorders | Systematic Assessment |
|
| Chest pain | General disorders | Systematic Assessment |
|
| Chills | General disorders | Systematic Assessment |
|
| Face oedema | General disorders | Systematic Assessment |
|
| Fatigue | General disorders | Systematic Assessment |
|
| Gait disturbance | General disorders | Systematic Assessment |
|
| Generalised oedema | General disorders | Systematic Assessment |
|
| Local swelling | General disorders | Systematic Assessment |
|
| Localised oedema | General disorders | Systematic Assessment |
|
| Malaise | General disorders | Systematic Assessment |
|
| Mucosal inflammation | General disorders | Systematic Assessment |
|
| Oedema peripheral | General disorders | Systematic Assessment |
|
| Pain | General disorders | Systematic Assessment |
|
| Pyrexia | General disorders | Systematic Assessment |
|
| Anorectal cellulitis | Infections and infestations | Systematic Assessment |
|
| Bacteraemia | Infections and infestations | Systematic Assessment |
|
| Hyperbilirubinaemia | Hepatobiliary disorders | Systematic Assessment |
|
| Abscess | Infections and infestations | Systematic Assessment |
|
| Abscess limb | Infections and infestations | Systematic Assessment |
|
| Burkholderia infection | Infections and infestations | Systematic Assessment |
|
| Cellulitis | Infections and infestations | Systematic Assessment |
|
| Clostridium colitis | Infections and infestations | Systematic Assessment |
|
| Clostridium difficile colitis | Infections and infestations | Systematic Assessment |
|
| Candida infection | Infections and infestations | Systematic Assessment |
|
| Diverticulitis | Infections and infestations | Systematic Assessment |
|
| Folliculitis | Infections and infestations | Systematic Assessment |
|
| Escherichia bacteraemia | Infections and infestations | Systematic Assessment |
|
| Lung infection | Infections and infestations | Systematic Assessment |
|
| Oral candidiasis | Infections and infestations | Systematic Assessment |
|
| Oral herpes | Infections and infestations | Systematic Assessment |
|
| Pharyngitis | Infections and infestations | Systematic Assessment |
|
| Pneumocystis jirovecii pneumonia | Infections and infestations | Systematic Assessment |
|
| Pneumonia | Infections and infestations | Systematic Assessment |
|
| Pneumonia fungal | Infections and infestations | Systematic Assessment |
|
| Pneumonia bacterial | Infections and infestations | Systematic Assessment |
|
| Pneumonia viral | Infections and infestations | Systematic Assessment |
|
| Pseudomonal bacteraemia | Infections and infestations | Systematic Assessment |
|
| Pseudomonas infection | Infections and infestations | Systematic Assessment |
|
| Rash pustular | Infections and infestations | Systematic Assessment |
|
| Sepsis | Infections and infestations | Systematic Assessment |
|
| Septic arthritis staphylococcal | Infections and infestations | Systematic Assessment |
|
| Staphylococcal bacteraemia | Infections and infestations | Systematic Assessment |
|
| Septic shock | Infections and infestations | Systematic Assessment |
|
| Sinusitis | Infections and infestations | Systematic Assessment |
|
| Trichosporon infection | Infections and infestations | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | Systematic Assessment |
|
| Urinary tract infection enterococcal | Infections and infestations | Systematic Assessment |
|
| Viral sinusitis | Infections and infestations | Systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Eye injury | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Subdural hemorrhage | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Transfusion reaction | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Joint injury | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Procedural pain | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | Systematic Assessment |
|
| Activated partial thromboplastin time prolonged | Investigations | Systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | Systematic Assessment |
|
| Blood alkaline phosphatase increased | Investigations | Systematic Assessment |
|
| Blood bilirubin increased | Investigations | Systematic Assessment |
|
| Blood creatinine increased | Investigations | Systematic Assessment |
|
| Blood creatinine decreased | Investigations | Systematic Assessment |
|
| International normalised ratio increased | Investigations | Systematic Assessment |
|
| Blood lactate dehydrogenase increased | Investigations | Systematic Assessment |
|
| Blood urea increased | Investigations | Systematic Assessment |
|
| Neutrophil count decreased | Investigations | Systematic Assessment |
|
| Platelet count decreased | Investigations | Systematic Assessment |
|
| Weight decreased | Investigations | Systematic Assessment |
|
| White blood cell count decreased | Investigations | Systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | Systematic Assessment |
|
| Fluid overload | Metabolism and nutrition disorders | Systematic Assessment |
|
| Fluid retention | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypercalcaemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hyperglycaemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hyperkalaemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypermagnesaemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypernatraemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hyperphosphataemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hyperuricaemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypoalbunaemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypocalcaemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypokalaemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypomagnaesemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hyponatraemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypophosphataemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Metabolic acidosis | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypouricaemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Arthritis | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Bone pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Flank pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Groin pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Joint swelling | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Muscular weakness | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Neck pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Carcinoma in situ of skin | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| Squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | Systematic Assessment |
|
| Dysguesia | Nervous system disorders | Systematic Assessment |
|
| Haemorrhage inctracranial | Nervous system disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | Systematic Assessment |
|
| Lethargy | Nervous system disorders | Systematic Assessment |
|
| Neuropathy peripheral | Nervous system disorders | Systematic Assessment |
|
| Restless legs syndrome | Nervous system disorders | Systematic Assessment |
|
| Tremor | Nervous system disorders | Systematic Assessment |
|
| Paraesthesia | Nervous system disorders | Systematic Assessment |
|
| Syncope | Nervous system disorders | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | Systematic Assessment |
|
| Confusional state | Psychiatric disorders | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | Systematic Assessment |
|
| Mental status changes | Psychiatric disorders | Systematic Assessment |
|
| Depression | Psychiatric disorders | Systematic Assessment |
|
| Dysuria | Renal and urinary disorders | Systematic Assessment |
|
| Haematuria | Renal and urinary disorders | Systematic Assessment |
|
| Urinary retention | Renal and urinary disorders | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Dysphonia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Hiccups | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Nasal crusting | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Nasal dryness | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pleuritic pain | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pneumonia respiratory synctial viral | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Sinus congestion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Sneezing | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Blister | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Dermatitis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Drug eruption | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Erythema | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Hyperhidrosis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Petechiae | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Rash erythematous | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Rash maculo-papular | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Skin hypopigmentation | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Skin lesion | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Swelling face | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Endodontic procedure | Surgical and medical procedures | Systematic Assessment |
|
| Micrographic skin surgery | Surgical and medical procedures | Systematic Assessment |
|
| Deep vein thrombosis | Vascular disorders | Systematic Assessment |
|
| Haematoma | Vascular disorders | Systematic Assessment |
|
| Hypertension | Vascular disorders | Systematic Assessment |
|
| Hypotension | Vascular disorders | Systematic Assessment |
|
| Orthostatic hypotension | Vascular disorders | Systematic Assessment |
|
| Pallor | Vascular disorders | Systematic Assessment |
|
Not provided
Not provided
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006841 |
| Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |
| D000617 | Aminoglycosides |
| D006027 | Glycosides |
| D002241 | Carbohydrates |
| D003562 | Cytidine |
| D011741 | Pyrimidine Nucleosides |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001087 | Arabinonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D001372 | Aza Compounds |
| D012263 | Ribonucleosides |
| D000880 | Anthraquinones |
| D000095322 | Anthrones |
| D000873 | Anthracenes |
| D011809 | Quinones |
| D011034 | Podophyllotoxin |
| D013764 | Tetrahydronaphthalenes |
| D009281 | Naphthalenes |
| D005960 | Glucosides |
| D003115 | Colony-Stimulating Factors |
| D006023 | Glycoproteins |
| D006001 | Glycoconjugates |
| D016298 | Hematopoietic Cell Growth Factors |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011506 | Proteins |
| D001685 | Biological Factors |